IPO Databook: Braveheart Bio (BRVE US) - Jul 2026

152 Views01 Aug 2026 10:09

SUMMARY

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. Its lead candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor for.
BHB-1893 is being developed for HCM, which affects over 700,000 US individuals. Phase 2 oHCM Study 201 showed an 86% complete response rate.
As of March 31, 2026, cash and cash equivalents were $80,576, with a net loss of $(14,280) for the three months.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream